Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...

Warren Buffett says that if he were to start again, he’d look for old-fashioned value stocks. Stephen Wright thinks there’s an unusual one on offer. The post Why I’m considering considering breaking ...

2-Year U.S. Treasury Note Continuous Contract $103.668-0.066-0.06% 5-Year U.S. Treasury Note Continuous Contract $108.367-0.156-0.14% 10-Year U.S. Treasury Note Continuous Contract $111.156-0.156 ...

The complete list of series and movies that are currently locked from Netflix’s advertising tier in the US.